A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Philip J Mease,Lingnan Li,Hasan Tahir,Frank Behrens,Sreekumar G Pillai,Philip S Helliwell,Peter Nash,Paul Emery,Melinda Gooderham,Soyi Liu Leage,Hong Liu-Seifert,Eswar Krishnan,Josef S Smolen

doi:10.1136/annrheumdis-2019-215386

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Philip J Mease, Lingnan Li + Show 11 more

Open Access

https://doi.org/10.1136/annrheumdis-2019-215386

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Sep 28, 2019
Citations: 216	License type: open-access

Affiliation: Swedish Medical Center, Eli Lilly (United States), Barts Health NHS Trust, Fraunhofer Institute for Translational Medicine and Pharmacology, Goethe University Frankfurt, Fraunhofer Institute for Molecular Biology and Applied Ecology, NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, University of Queensland, Leeds Teaching Hospitals NHS Trust, SKiN Health, Medical University of Vienna

#Ixekizumab #Safety Of Ixekizumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesTo compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.